SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 2.2% Passive Stake in Neumora Therapeutics
Beneficial Ownership Report
FMR LLC and its affiliate Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 2.2% of Neumora Therapeutics Inc.'s common stock as of March 31, 2025.
Summary
- FMR LLC and Abigail P. Johnson collectively beneficially own 3,496,316 shares of Neumora Therapeutics Inc. common stock.
- This ownership represents 2.2% of the total outstanding common stock of Neumora Therapeutics Inc.
- FMR LLC holds sole voting power over 3,491,135 shares and sole dispositive power over 3,496,316 shares.
- Abigail P. Johnson, as a control person of FMR LLC, is also deemed to beneficially own 3,496,316 shares with sole dispositive power.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, providing neutral information without positive or negative operational or financial performance details for the issuer.
Positives
- The disclosure indicates continued institutional investment in Neumora Therapeutics Inc. by a major financial institution, FMR LLC.
- The filing explicitly states that the shares are not held for the purpose of changing or influencing control of the issuer, suggesting a passive investment stance.
Negatives
- The reported beneficial ownership of 2.2% is below the 5% threshold typically associated with significant activist or influential stakes, indicating a relatively small passive investment.
Risks
- The document itself does not detail risks related to Neumora Therapeutics Inc.'s operations or financial health; it is solely a disclosure of ownership.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Neumora Therapeutics Inc.'s future performance or strategic direction. It is solely a disclosure of current beneficial ownership.
Management Comments
- "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing is a routine disclosure of institutional ownership, common in the financial industry, and does not provide specific insights into Neumora Therapeutics Inc.'s competitive position or broader industry trends. It merely indicates that a significant asset manager, FMR LLC, holds a passive stake in the company.
Comparison to Industry Standards
- This document does not contain information that allows for a comparison of Neumora Therapeutics Inc.'s results to global benchmarks or specific comparable companies/projects. It is a disclosure of an investor's stake, not the company's operational or financial performance.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director, Chairman, and Chief Executive Officer of FMR LLC | N/A | Abigail P. Johnson | N/A | N/A (role within reporting entity, not issuer) |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Ownership Structure Disclosure | The document describes the ownership structure and voting agreement within FMR LLC, noting that Johnson family members, including Abigail P. Johnson, are predominant owners of Series B voting common shares and have a shareholders' voting agreement, forming a controlling group with respect to FMR LLC. | N/A | Provides transparency on the control structure of the reporting entity (FMR LLC), not the issuer (Neumora Therapeutics Inc.). |
Related Party Transactions
- The document describes the relationship between FMR LLC and Abigail P. Johnson, noting that Johnson family members are predominant owners of FMR LLC and have a shareholders' voting agreement. This details an internal related party structure for the reporting entity, not a transaction with Neumora Therapeutics Inc.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake, confirming a degree of institutional confidence.
- Employees, Customers, Suppliers, Creditors: No direct impact from this ownership disclosure.
Next Steps
- The document does not outline any specific future actions, events, or milestones for Neumora Therapeutics Inc. or the reporting persons beyond the routine nature of SEC filings.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | Effective date of Power of Attorney for FMR LLC. |
| 01/26/2023 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 03/31/2025 | Date of event requiring the filing of this statement (reporting period end date). |
| 05/09/2025 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Neumora Therapeutics Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, institutional investor, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.